Phase 4 Migraine Trial, Recruiting NCT06485726 Sponsor: Kafrelsheikh University Condition: Migraine
Back to Migraine

Phase 4 Migraine Trial, Recruiting

NCT06485726
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old and have been diagnosed with migraine (with no previous treatment for it) according to standard international guidelines.

Who may not be able to join:

  • You have a major neurological condition such as epilepsy, stroke, multiple sclerosis, mitochondrial disease, a brain tumour, or essential tremors.
  • You have a serious ongoing illness such as cancer, connective tissue disease, or liver or kidney disease.
  • You have high blood pressure (readings above certain levels recorded on at least three separate occasions) (confirm with trial site).
  • You have diabetes, based on blood sugar or HbA1c test results above certain levels (confirm with trial site).
  • You have heart valve problems, coronary heart disease, a slow or irregular heartbeat, heart block, or heart failure.
  • You have previously taken any medication specifically to prevent migraines.
  • You have any known allergy or medical reason that prevents you from taking the medications used in this study (confirm with trial site).
  • You have asthma or chronic obstructive pulmonary disease (a long-term lung condition).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: mohamed G. Zeinhom, MD, neurology department kafr el-sheikh university

Phone: 2001009606828

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Kafrelsheikh University
Registry
ClinicalTrials.gov
Start date
23 January 2023
Est. completion
1 July 2024

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The change in migraine days per 28 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov